Clinical Trials Logo

Filter by:
NCT ID: NCT05040932 Completed - Cancer Clinical Trials

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Start date: December 7, 2021
Phase: Phase 1
Study type: Interventional

YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D) of YH004, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody (Toripalimab) in the treatment of advanced solid tumors and relapsed or refractory non-Hodgkin Lymphoma.

NCT ID: NCT05040698 Completed - Clinical trials for Hidradenitis Suppurativa

Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.

NCT ID: NCT05039268 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Start date: November 25, 2021
Phase: Phase 2
Study type: Interventional

Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS).

NCT ID: NCT05036512 Completed - Sickle Cell Disease Clinical Trials

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

Start date: December 9, 2020
Phase: Phase 1
Study type: Interventional

This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.

NCT ID: NCT05035654 Completed - Chronic Sinusitis Clinical Trials

LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)

Start date: November 23, 2021
Phase: Phase 2
Study type: Interventional

This study will assess the safety, tolerability, pharmacokinetics and efficacy of two LYR-220 designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior functional endoscopic sinus surgery.

NCT ID: NCT05034484 Completed - Healthy Volunteers Clinical Trials

A Study of ALPN-303 in Adult Healthy Volunteers

RUBY-1
Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.

NCT ID: NCT05033483 Completed - Anemia Clinical Trials

Do Iron Supplements Impact the Gut Microbiome of Women of Reproductive Age?

Start date: August 31, 2021
Phase: N/A
Study type: Interventional

In this randomised controlled trial the investigators will determine whether taking iron supplements compared to placebo for 21 days alters the bacteria (microbiome) in the large intestine of non-pregnant female participants.

NCT ID: NCT05033080 Completed - Cystic Fibrosis Clinical Trials

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Start date: September 14, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study evaluates the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who were heterozygous for F508del and a minimal function mutation (F/MF participants).

NCT ID: NCT05032729 Completed - Sleep Clinical Trials

Nutritional Intervention to Enhance Sleep Quality and Quantity in Athletes

Start date: March 14, 2022
Phase: N/A
Study type: Interventional

The primary objective is to assess the impact of two nutritional interventions vs. placebo on objective and subjective sleep measures in athletes. Participants receive one beverage on each of three consecutive nights in a randomized manner. It is hypothesized the two nutritional interventions will result in significant improvements in sleep onset latency, and will not result in a negative impact on next-day cycling performance. The secondary objective is to assess the impact of the nutritional interventions vs. placebo on next-morning performance (physical, cognitive function, and balance).

NCT ID: NCT05030311 Completed - Clinical trials for Chronic Spontaneous Urticaria

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

REMIX-1
Start date: November 30, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.